| Manda Louise Chatelain, NP | |
|
1331 N 7th St Ste 405, Phoenix, AZ 85006-2754 | |
| (602) 254-3151 | |
| Not Available |
| Full Name | Manda Louise Chatelain |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 22 Years |
| Location | 1331 N 7th St Ste 405, Phoenix, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124049838 | NPI | - | NPPES |
| 860224285 | Other | AZ | TAX ID |
| 188316200 | Other | AZ | DEPT OF LABOR ID |
| 1Z9797 | Other | AZ | HEALTHNET |
| CD4863 | Other | AZ | RAILROAD MEDICARE ID |
| 751679 | Medicaid | AZ | |
| AZ0143190 | Other | AZ | BC BS ID |
| Facility Name | Location | Facility Type |
|---|---|---|
| Banner Thunderbird Medical Center | Glendale, AZ | Hospital |
| Banner - University Medical Center Phoenix | Phoenix, AZ | Hospital |
| Banner Desert Medical Center | Mesa, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Center For Orthopedic Research And Education Llc | 0345287322 | 236 |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Long-term leaves of absence tied to stress-related diagnoses are often preceded by a long period without any secure and comforting social relations. This is shown in a recently published study in public health science at Karlstad University in Sweden.
A recent bioRxiv* preprint offers a powerful risk assessment approach to estimate the risk of bat exposure to SARS-CoV-2 from humans during their interactions in the wild.
The phenomenon of false memory has been well-documented: In many court cases, defendants have been found guilty based on testimony from witnesses and victims who were sure of their recollections, but DNA evidence later overturned the conviction.
› Verified 1 days ago
| Entity Name | Center For Orthopedic Research And Education Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427095801 PECOS PAC ID: 0345287322 Enrollment ID: O20050412000087 |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Long-term leaves of absence tied to stress-related diagnoses are often preceded by a long period without any secure and comforting social relations. This is shown in a recently published study in public health science at Karlstad University in Sweden.
A recent bioRxiv* preprint offers a powerful risk assessment approach to estimate the risk of bat exposure to SARS-CoV-2 from humans during their interactions in the wild.
The phenomenon of false memory has been well-documented: In many court cases, defendants have been found guilty based on testimony from witnesses and victims who were sure of their recollections, but DNA evidence later overturned the conviction.
› Verified 1 days ago
| Entity Name | Arizona Neurosurgery And Spine Specialists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083801054 PECOS PAC ID: 3870681695 Enrollment ID: O20071113000159 |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Long-term leaves of absence tied to stress-related diagnoses are often preceded by a long period without any secure and comforting social relations. This is shown in a recently published study in public health science at Karlstad University in Sweden.
A recent bioRxiv* preprint offers a powerful risk assessment approach to estimate the risk of bat exposure to SARS-CoV-2 from humans during their interactions in the wild.
The phenomenon of false memory has been well-documented: In many court cases, defendants have been found guilty based on testimony from witnesses and victims who were sure of their recollections, but DNA evidence later overturned the conviction.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Manda Louise Chatelain, NP 18444 N 25th Ave Ste 310, Phoenix, AZ 85023-1266 Ph: (866) 974-2673 | Manda Louise Chatelain, NP 1331 N 7th St Ste 405, Phoenix, AZ 85006-2754 Ph: (602) 254-3151 |
News Archive
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Long-term leaves of absence tied to stress-related diagnoses are often preceded by a long period without any secure and comforting social relations. This is shown in a recently published study in public health science at Karlstad University in Sweden.
A recent bioRxiv* preprint offers a powerful risk assessment approach to estimate the risk of bat exposure to SARS-CoV-2 from humans during their interactions in the wild.
The phenomenon of false memory has been well-documented: In many court cases, defendants have been found guilty based on testimony from witnesses and victims who were sure of their recollections, but DNA evidence later overturned the conviction.
› Verified 1 days ago